[2024/12/06] Gene and Cell Therapy- weekly digest from PackGene

Dec 6, 2024

Featured

Dec 04 GSK offers Rgenta up to $500M biobucks per target in RNA deal read more »
Dec 04 Sickle cell gene therapies included in new Medicaid access model read more »
Nov 28 Prime editing: therapeutic advances and mechanistic insights read more »
News
Dec 04 Researchers discover cell-type-specific link between alternative splicing and autoimmune disease inheritance read more »
Dec 04 Viral Vaccines Market to be Worth $64.18 Billion by 2031 - Exclusive Report by Meticulous Research® read more »
Dec 04 RNA-targeting drug relaxes muscles in myotonic dystrophy mice read more »
Dec 03 Cartesian tees up Phase 3 mRNA CAR-T study in myasthenia gravis read more »
Dec 03 Medicare Advantage set to benefit under Trump read more »
Dec 02 Antibiotic Resistance Can Emerge If Bacteria Lose rRNA Modifications read more »
Articles
Dec 04 2024: research in review | Nature Biotechnology read more »
Dec 04 Top ten news stories in 2024 | Nature Biotechnology read more »
Dec 04 Modulation of TCR stimulation and pifithrin-α improves the genomic safety profile of CRISPR-engineered human T cells read more »
Dec 02 UBA1 inhibition sensitizes cancer cells to PARP inhibitors read more »
Nov 28 Prevalence of Neutralizing Antibodies Against AAV Serotypes 2 and 9 in Healthy Participants from Multiple Centers Across China and Patients with DMD/BMD read more »
Nov 25 Managing Allorejection in Off-the-Shelf CAR-Engineered Cell Therapies read more »
Nov 21 PCRX-201, a novel IL-1Ra gene therapy treatment approach for low back pain resulting from intervertebral disc degeneration read more »
Nov 20 Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants read more »

PackGene’s Newsletter

Receive the latest news and insights to your inbox.

Subscribe Now
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

AAV Packaging Services

We have developed a series of proprietary technologies that greatly improve AAV production outcomes including titer, purity, potency, and consistency.

READ MORE

Off-the-Shelf AAV Products

We offer a library of carefully designed and pre-stocked AAV vectors for a wide variety of experimental needs.

READ MORE